Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 18/20 | 0.48 |
| ▸ | DRD2 | P14416 | 11/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880343 | 0.80 | DRD3 (0.45) | DRD3DRD2KCNH2HRH1CHRM1 | |
| SCHEMBL17713118 | 0.80 | DRD3 (0.47) | DRD3DRD2KCNH2HRH1CHRM1 | |
| SCHEMBL1877771 | 0.79 | DRD3 (0.45) | DRD3DRD2KCNH2HRH1CHRM1 | |
| SCHEMBL1881964 | 0.71 | HSD11B1 (0.52) | DRD3DRD2 | |
| SCHEMBL1877242 | 0.71 | TLR8 (0.33) | DRD3DRD2KCNH2HRH1 | |
| SCHEMBL16480593 | 0.71 | DRD3 (0.40) | DRD3DRD2KCNH2HRH1CHRM1 | |
| SCHEMBL1876761 | 0.69 | TLR8 (0.45) | — | |
| SCHEMBL4877460 | 0.68 | DRD3 (0.39) | DRD3DRD2KCNH2HRH1CHRM1 | |
| SCHEMBL13895695 | 0.66 | DRD3 (0.39) | DRD3DRD2KCNH2HRH1 | |
| SCHEMBL1878256 | 0.66 | HSD11B1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR3C, TACR2 | DRD3 1/4885DRD2 11/4885KCNH2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.